$KITE to Report Fourth Quarter and Full Year 2014 Financial Results

Biotech Stocks

Kite Pharma to Report Fourth Quarter and Full Year 2014 Financial Results on March 26th, 2015

SANTA MONICA, Calif., March 25, 2015 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products based on chimeric antigen receptor (CAR) and T cell receptor (TCR) gene therapy for the treatment of cancer, today announced that it will issue a press release with its financial results and company highlights for the fourth quarter and year ended December 31, 2014, on Thursday, March 26, 2015.

About Kite Pharma

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT(TM) designed to restore the immune system’s ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com.

Kite Pharma
Cynthia M. Butitta
Chief Financial Officer and Chief Operating Officer
For Media: Justin Jackson
For Investor Inquiries: Lisa Burns and Nancy Yu
Burns McClellan
[email protected]
[email protected]
[email protected]


Please enter your comment!
Please enter your name here